pyridoxamine has been researched along with Hypertrophy, Left Ventricular in 1 studies
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, ET | 1 |
| Liang, JT | 1 |
| Wu, MS | 1 |
| Chang, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Serum Levels of Advanced Glycation End-products After Dietary Intervention in Hypertensive Patients: Study Protocol of a Randomized Clinical Trial.[NCT02848677] | Phase 2 | 120 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for pyridoxamine and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation.
Topics: Aging; Animals; Aorta; Atherosclerosis; Body Weight; Collagen; Elasticity; Hypertrophy, Left Ventric | 2011 |